Disease etiology and outcomes after atezolizumab plus bevacizumab in hepatocellular carcinoma: Post-hoc analysis of IMbrave150

Posted on March 7, 2023 by Gastroenterology Journal
This entry was posted in News. Bookmark the permalink.